Deals
Eli Lilly Agrees to Buy Cancer-Drug Company for $1.6 Billion
- ARMO BioSciences developing a series of immuno-oncology drugs
- Lilly expects $50-a-share-deal to close in the second quarter
This article is for subscribers only.
Eli Lilly & Co. agreed to acquire ARMO BioSciences Inc. for about $1.6 billion in cash, in a deal that would add some promising cancer therapies to the pharmaceutical giant’s pipeline.
Under the terms of the proposed transaction, Lilly will commence a tender offer to buy all shares of ARMO for $50 a share, according to a news release announcing the deal, a 68 percent premium relative to the $29.80 that the Redwood City, California-based company’s stock closed at in New York trading on Wednesday.